StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

Stock analysts at StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

A number of other research firms have also weighed in on CTSO. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Friday. HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Price Performance

Shares of CTSO opened at $1.04 on Friday. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.59. The firm’s 50-day simple moving average is $0.92 and its two-hundred day simple moving average is $1.02. The stock has a market cap of $56.87 million, a PE ratio of -2.89 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTSO. Geode Capital Management LLC raised its stake in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares during the last quarter. Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents during the third quarter valued at $51,000. Finally, Sargent Investment Group LLC increased its holdings in Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares in the last quarter. 32.87% of the stock is owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.